A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC) - Trial NCT06333678
Access comprehensive clinical trial information for NCT06333678 through Pure Global AI's free database. This Phase 2 trial is sponsored by Memorial Sloan Kettering Cancer Center and is currently Recruiting. The study focuses on Non-Small Cell Lung Cancer. Target enrollment is 160 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Memorial Sloan Kettering Cancer Center
Timeline & Enrollment
Phase 2
Mar 20, 2024
Mar 01, 2027
Primary Outcome
Progression-free survival (PFS)
Summary
In this study, the researchers will look at whether having participants switch from
 durvalumab to sotorasib when they have detectable minimal residual disease (MRD) is an
 effective treatment approach for locally advanced non-small cell lung cancer (LA-NSCLC). The
 researchers will see whether this switch to sotorasib can control LANSCLC longer compared to
 the treatment approach of staying on durvalumab (and not switching to sotorasib).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06333678
Non-Device Trial